A couple ASCO 2010 related links

[Rich66]

http://abstract.asco.org/CatAbstView_74_3_AA.html

http://www.mbcnetwork.org/blog/index.php


CCO Independent Conference Coverage of the 2010 American Society of Clinical Oncology Annual Meeting (audio links)
http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202010.aspx

[schoonder]

One Genentech abstract at ASCO pertaining to naked T-DM1 treatment clearly showed that participants that over-expressed Her2+ benefitted more from this treatment than her2+ normal candidates. Stronger results were reported in both progression free survival time as well in operational response.
http://www.medpagetoday.com/MeetingCoverage/ASCO/20498"

[Rich66]

Wow. Naked treatment. They'll try anything these days. Whatever works.

[schoonder]

Oops, naked t-dm1 should read stand-alone t-dm1 treatment.